Clinical Trial Update: A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating chemoradiation in combination with tislelizumab as first-line therapy for advanced Esophageal Squamous Cell Carcinoma, cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Renmin Hospital of Wuhan University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING